Cantor Fitzgerald reiterates Gilead Sciences stock rating at overweight

Gilead shares trade at $139.71 (up 24.5% over six months) and are near InvestingPro Fair Value of $140.04 while Cantor Fitzgerald reiterates an Overweight $155 target. Yeztugo prescriptions rose 10% week-over-week and finished the quarter up ~84% quarter-over-quarter (UBS notes Feb sales +56% month-over-month; DB forecasts Q1'26 Yeztugo sales of ~$118M; consensus ~$145M). Corporate actions include an extended tender offer for Arcellx at $115.00/share plus a $5 CVR (expiry Apr 24, 2026) and the acquisition of Ouro Medicines for $1.7B upfront plus up to $500M in milestones, bolstering Gilead's immunology pipeline; multiple brokers reiterate positive ratings (UBS/Deutsche Bank Buy; Bernstein/SocGen Outperform; Goldman Neutral $125 PT).

Analysis

Prescription momentum concentrated in a newly launched franchise creates asymmetric earnings risk: if refill and buy‑and‑bill adoption continue to outpace panel data, EPS beats can cascade through consensus over two consecutive quarters and re-rate the multiple; conversely, a DTC‑driven front‑load would leave a pronounced hangover once acquisition efficiency normalizes. IQVIA undercapture of buy‑and‑bill is not a minor data quirk — it is a systematic measurement bias that can produce quarterly revisions and then a sharp reprice of forward estimates when management confirms actual channel mix.

The recent bolt‑on R&D acquisition materially changes the company’s exposure from pure small‑molecule/antiviral economics to higher‑capital, cell‑engager dynamics; this shifts risk from straightforward volume & pricing to development binary risk and COGS/manufacturing scale challenges over 12–36 months. The parallel tender activity signals the acquirer is willing to pay control premia for platform assets, which compresses expected multiples on remaining small‑cap immunology targets and creates a near-term deal pipeline that could accelerate further tuck‑ins.

Key near‑term catalysts are refill cadence and any official commentary reconciling IQVIA vs internal buy‑and‑bill flows (days–weeks), plus formal Q2 sales cadence and pipeline readouts over the next 6–18 months. Tail risks include payer restrictions or tougher formulary dynamics that can flip secular uptake assumptions, and integration/financing pressure from acquisitions that can temporarily crowd out buybacks or dividend policy. The consensus miss is twofold: the market may underprice buy‑and‑bill upside while overpaying for durability of DTC‑sourced demand — both outcomes argue for convex, event‑driven positioning rather than a simple long-only exposure.

Key Decisions for Investors

• Initiate a tactical 2–3% long position in GILD (6–12 month horizon): structure as 60% stock + 40% long-dated call optionality (e.g., Jan‑2028 calls) to capture upside if buy‑and‑bill/refill data surprise upward; downside is limited to ~10–15% equity drawdown if payer pressure or acquisition financing shock emerges.
• Merger arb on ACLX (time to tender close, weeks–months): buy ACLX to capture spread to the tender consideration, hedge event risk by shorting a portion of GILD exposure if concerned about deal financing or regulatory pushback; primary risk is deal break / competing bidder, reward is capture of spread (target IRR 8–15% over life of arb).
• Hedge near‑term operational risk: buy 3‑month puts on GILD sized to cover 30–50% of equity exposure ahead of two catalysts (refill metric release and quarterly sales cadence); this limits tail loss from an unexpected payer or guidance reset at modest premium cost.
• Watchlist & optionality in small‑cap immunology: screen for assets with clear platform chemistry and early BCMA exposure and buy 6–12 month call spreads (fund small position sizes) to play continued M&A activity; reward is >2x on successful takeouts, risk is binary trial/valuation compression.